Exploring Natural Killer Cell Immunotherapeutics to Reduce Neuroinflammation in Alzheimer’s & FTD

• Deciphering Troculeucel’s mechanism of action in reducing CSF neuroinflammatory and protein biomarkers
• Ensuring auto-activated T cell targeting without affecting resting T cells to fundamentally address neuroinflammation
• Reviewing the early clinical efficacy of Troculeucel in AD and FTD patients

Speakers:

Paul Song

Chairman & Chief Executive Officer

NKGen Biotech